360 related articles for article (PubMed ID: 18287446)
1. Nephrogenic systemic fibrosis: a report of 29 cases.
Shabana WM; Cohan RH; Ellis JH; Hussain HK; Francis IR; Su LD; Mukherji SK; Swartz RD
AJR Am J Roentgenol; 2008 Mar; 190(3):736-41. PubMed ID: 18287446
[TBL] [Abstract][Full Text] [Related]
2. Gadolinium-based contrast exposure, nephrogenic systemic fibrosis, and gadolinium detection in tissue.
Wiginton CD; Kelly B; Oto A; Jesse M; Aristimuno P; Ernst R; Chaljub G
AJR Am J Roentgenol; 2008 Apr; 190(4):1060-8. PubMed ID: 18356456
[TBL] [Abstract][Full Text] [Related]
3. Gadolinium-enhanced MR imaging and nephrogenic systemic fibrosis: retrospective study of a renal replacement therapy cohort.
Collidge TA; Thomson PC; Mark PB; Traynor JP; Jardine AG; Morris ST; Simpson K; Roditi GH
Radiology; 2007 Oct; 245(1):168-75. PubMed ID: 17704357
[TBL] [Abstract][Full Text] [Related]
4. Gadolinium and nephrogenic systemic fibrosis: association or causation.
Kurtkoti J; Snow T; Hiremagalur B
Nephrology (Carlton); 2008 Jun; 13(3):235-41. PubMed ID: 18221255
[TBL] [Abstract][Full Text] [Related]
5. Nephrogenic systemic fibrosis after exposure to gadolinium in patients with renal failure.
Othersen JB; Maize JC; Woolson RF; Budisavljevic MN
Nephrol Dial Transplant; 2007 Nov; 22(11):3179-85. PubMed ID: 17890246
[TBL] [Abstract][Full Text] [Related]
6. Nephrogenic systemic fibrosis: center case review.
Lauenstein TC; Salman K; Morreira R; Tata S; Tudorascu D; Baramidze G; Singh-Parker S; Martin DR
J Magn Reson Imaging; 2007 Nov; 26(5):1198-203. PubMed ID: 17969162
[TBL] [Abstract][Full Text] [Related]
7. Gadolinium-associated nephrogenic systemic fibrosis.
Schlaudecker JD; Bernheisel CR
Am Fam Physician; 2009 Oct; 80(7):711-4. PubMed ID: 19817341
[TBL] [Abstract][Full Text] [Related]
8. Nephrogenic systemic fibrosis: is gadolinium the missing piece to the puzzle?
Bennett LK; Garrett AL
Cutis; 2008 May; 81(5):421-6. PubMed ID: 18543594
[TBL] [Abstract][Full Text] [Related]
9. Recent topics related to nephrogenic systemic fibrosis associated with gadolinium-based contrast agents.
Kitajima K; Maeda T; Watanabe S; Ueno Y; Sugimura K
Int J Urol; 2012 Sep; 19(9):806-11. PubMed ID: 22571387
[TBL] [Abstract][Full Text] [Related]
10. Incidence of nephrogenic systemic fibrosis at a large university hospital in Sweden.
Alhadad A; Sterner G; Svensson Å; Alhadad H; Leander P
Scand J Urol Nephrol; 2012 Feb; 46(1):48-53. PubMed ID: 22008005
[TBL] [Abstract][Full Text] [Related]
11. Gadolinium-containing magnetic resonance imaging contrast and nephrogenic systemic fibrosis: a case-control study.
Kallen AJ; Jhung MA; Cheng S; Hess T; Turabelidze G; Abramova L; Arduino M; Guarner J; Pollack B; Saab G; Patel PR
Am J Kidney Dis; 2008 Jun; 51(6):966-75. PubMed ID: 18501784
[TBL] [Abstract][Full Text] [Related]
12. Association of gadolinium based magnetic resonance imaging contrast agents and nephrogenic systemic fibrosis.
Bhave G; Lewis JB; Chang SS
J Urol; 2008 Sep; 180(3):830-5; discussion 835. PubMed ID: 18635232
[TBL] [Abstract][Full Text] [Related]
13. Gadolinium-based contrast media and the development of nephrogenic systemic fibrosis in patients with renal insufficiency.
Chewning RH; Murphy KJ
J Vasc Interv Radiol; 2007 Mar; 18(3):331-3. PubMed ID: 17377176
[TBL] [Abstract][Full Text] [Related]
14. Tissue gadolinium deposition and fibrosis mimicking nephrogenic systemic fibrosis (NSF)-subclinical nephrogenic systemic fibrosis?
Boyd AS; Sanyal S; Abraham JL
J Am Acad Dermatol; 2010 Feb; 62(2):337-42. PubMed ID: 19939504
[TBL] [Abstract][Full Text] [Related]
15. Nephrogenic systemic fibrosis is found only among gadolinium-exposed patients with renal insufficiency: a case-control study from Denmark.
Elmholdt TR; Pedersen M; Jørgensen B; Søndergaard K; Jensen JD; Ramsing M; Olesen AB
Br J Dermatol; 2011 Oct; 165(4):828-36. PubMed ID: 21692765
[TBL] [Abstract][Full Text] [Related]
16. Nephrogenic systemic fibrosis: possible association with a predisposing infection.
Golding LP; Provenzale JM
AJR Am J Roentgenol; 2008 Apr; 190(4):1069-75. PubMed ID: 18356457
[TBL] [Abstract][Full Text] [Related]
17. Response to "Will dialysis prevent the development of nephrogenic systemic fibrosis after gadolinium-based contrast administration?".
Broome DR; Cottrell AC; Kanal E
AJR Am J Roentgenol; 2007 Oct; 189(4):W234-5. PubMed ID: 17885040
[No Abstract] [Full Text] [Related]
18. Will dialysis prevent the development of nephrogenic systemic fibrosis after gadolinium-based contrast administration?
Saab G; Abu-Alfa A
AJR Am J Roentgenol; 2007 Sep; 189(3):W169. PubMed ID: 17715089
[No Abstract] [Full Text] [Related]
19. Application of gadolinium-based contrast agents and prevalence of nephrogenic systemic fibrosis in a cohort of end-stage renal disease patients on hemodialysis.
Becker S; Walter S; Witzke O; Kreuter A; Kribben A; Mitchell A
Nephron Clin Pract; 2012; 121(1-2):c91-4. PubMed ID: 23182840
[TBL] [Abstract][Full Text] [Related]
20. [Nephrogenic systemic fibrosis].
Cavallini L; Abaterusso C; Bedogna V; Pertica N; Loschiavo C; Lupo A
G Ital Nefrol; 2008; 25(1):14-20. PubMed ID: 18264914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
